GLPwatch
Papers (10373)
Page 69 of 173, ranked by citation count.
- Orally administered intelligent self-ablating nanoparticles: a new approach to improve drug cellular uptake and intestinal absorption.
- Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes.
- STEP 1 for Effective Weight Control - Another First Step?
- Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.
- Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.
- Determination of liraglutide in rat plasma by a selective liquid chromatography-tandem mass spectrometry method: Application to a pharmacokinetics study.
- Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets.
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
- Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
- NMR Spectroscopy for Protein Higher Order Structure Similarity Assessment in Formulated Drug Products.
- A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus.
- Correlated increase of omentin-1 and adiponectin by exenatide, avandamet and dietary change in diet-induced obese rats.
- Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.
- Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.
- Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.
- Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: Sodium caprate (C<sub>10</sub>) and salcaprozate sodium (SNAC).
- Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice.
- The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes.
- Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice.
- Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes.
- Translating What Works: A New Approach to Improve Diabetes Management.
- Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials.
- Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials.
- Therapeutic Effects of Liraglutide, Oxytocin and Granulocyte Colony-Stimulating Factor in Doxorubicin-Induced Cardiomyopathy Model: An Experimental Animal Study.
- Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0 mg.
- Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series.
- Albiglutide: a unique GLP-1 receptor agonist.
- The glucagon-like peptide-1 receptor agonist liraglutide improves hypoxia-induced pulmonary hypertension in mice partly via normalization of reduced ET(B) receptor expression.
- Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.
- Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone.
- Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
- Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
- Semaglutide Reprograms Macrophages via the GLP-1R/PPARG/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth.
- Allergic Reaction to Exenatide and Lixisenatide but Not to Liraglutide: Unveiling Anaphylaxis to Glucagon-Like Peptide 1 Receptor Agonists.
- Clinical potential of treatment with semaglutide in type 2 diabetes patients.
- Semaglutide treatment for children with obesity: an observational study.
- Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation.
- Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.
- Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetes.
- Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity.
- The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice.
- [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
- The effect of metformin combined with liraglutide on gut microbiota of Chinese patients with type 2 diabetes.
- Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?
- Pancreatitis during treatment with liraglutide.
- Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
- A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
- Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
- The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes.
- Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes.
- Exenatide enhanced the antitumor efficacy on PD-1 blockade by the attenuation of neutrophil extracellular traps.
- Dual GIPR and GLP-1R agonist tirzepatide inhibits aeroallergen-induced allergic airway inflammation in mouse model of obese asthma.
- Factors Associated With Semaglutide Initiation Among Adults With Obesity.
- Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?
- Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective.
- Ramadan fasting: a study of changes in glucose profiles among patients with diabetes using continuous glucose monitoring.
- Effect of liraglutide on dietary lipid-induced insulin resistance in humans.
- Neonatal exendin-4 reduces growth, fat deposition and glucose tolerance during treatment in the intrauterine growth-restricted lamb.
- Semaglutide 6-months therapy of type 2 diabetes mellitus restores adipose progenitors potential to develop metabolically active adipocytes.
- The efficacy and safety of exenatide once weekly in patients with type 2 diabetes.